Premium
Downregulation and growth inhibitory role of FHL1 in lung cancer
Author(s) -
Niu Chang,
Liang Chaoyang,
Guo Juntang,
Cheng Long,
Zhang Hao,
Qin Xi,
Zhang Qunwei,
Ding Lihua,
Yuan Bin,
Xu Xiaojie,
Li Jiezhi,
Lin Jing,
Ye Qig
Publication year - 2011
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.26259
Subject(s) - lung cancer , carcinogenesis , cancer research , cyclin d1 , biology , downregulation and upregulation , cancer , cyclin e , cyclin d , cell cycle , medicine , biochemistry , gene
Four and a half Lin‐11, Isl‐1, Mac‐3 (LIM) protein 1 (FHL1) has been linked to carcinogenesis. However, the role of FHL1 in lung cancer remains unclear and the detailed mechanism underlying its tumor suppressive role is poorly understood. The purpose of this study was to examine FHL1 expression in lung cancer patients and to investigate how it was associated with lung cancer cell growth. Immunoblotting and immunohistochemistry showed that FHL1 protein was downregulated in over 90% of 80 lung cancer patients. FHL1 expression was strongly correlated with tumor histological types ( p < 10 −4 ) and the differentiation of the tumor ( p = 0.002). FHL1 inhibited anchorage‐dependent and ‐independent growth of human lung cancer cell lines. The inhibitory effects of FHL1 on lung cancer cell growth were associated with both the G1 and the G2/M cell cycle arrest concomitant with a marked inhibition of cyclin A, cyclin B1 and cyclin D as well as the induction of the cyclin dependent kinase inhibitors p21 (WAF1/CIP1) and p27 (Kip1). Direct intratumoral injection of an adenovirus expressing FHL1 dramatically suppressed the growth of A549 lung cancer cells in nude mice. Our data suggest that reduced expression of FHL1 may play an important role in the development and progression of lung cancer and that FHL1 may be a useful target for lung cancer gene therapy.